Pachilitate's Jan 2026 webinar brought together Ronit Slotky, Director of the Cell Therapies Manufacturing Facility at Hackensack University Medical Center, and Craig Martin, CEO of Orphan Therapeutics Accelerator, with moderation by Kimberley Barnes, President of Phacilitate. Together, they explored the three most pressing dimensions shaping CGT access in 2026:
- Point-of-care (PoC) manufacturing
- Set-up and scale, and creative operating models
- HTA evolution and the shift from rare to larger indications
Our panel shared real-world insights into where programmes lose momentum and how earlier, smarter collaboration can reduce access risk and avoid late-stage surprises. Key talking points included:
- Why approval no longer guarantees adoption
- The most common access objections CGTs face today
- What hospitals need before they can implement therapies
- Where early decisions create downstream access risk
- How collaboration improves real-world uptake
- What “access-ready” means in 2026
Download the Whitepaper by completing the form below:
![[White Paper] From breakthrough to bottleneck: Why cell and gene therapies still struggle at market access](https://cdn.asp.events/CLIENT_CL_Conf_BDA05934_5056_B731_4C9EEBBE0C2416C2/sites/phacilitate-2025/media/libraries/insights-resources/Phac-logo-600600.png/fit-in/700x9999/filters:no_upscale()){kind=logo}